Matthew Maxwell Donley Sells 65,902 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares in the company, valued at $5,915,648. This represents a 8.18 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Aurinia Pharmaceuticals Trading Up 7.3 %

Shares of NASDAQ:AUPH opened at $8.67 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -57.80 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The company has a 50 day moving average price of $8.13 and a 200 day moving average price of $7.86.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several large investors have recently modified their holdings of AUPH. Tang Capital Management LLC raised its position in shares of Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after purchasing an additional 1,200,000 shares during the period. State Street Corp increased its stake in Aurinia Pharmaceuticals by 2.3% in the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after purchasing an additional 64,949 shares in the last quarter. Vanguard Group Inc. raised its holdings in Aurinia Pharmaceuticals by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock worth $15,535,000 after buying an additional 112,113 shares during the period. Nuveen Asset Management LLC raised its holdings in Aurinia Pharmaceuticals by 10.2% during the 4th quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company’s stock worth $13,401,000 after buying an additional 138,054 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $9,662,000. 36.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.